Search
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalAfterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. … [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.
Synonyms: 2-chloro-N-(4-chloro-3-pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-Eladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigational[A253697,L43672] Before the approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter … By promoting the expression of AADC, eladocagene exuparvovec leads to the development of motor function in patients with AADC deficiency.
Exemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalIt irreversibly binds to the active site of the enzyme resulting in permanent inhibition. … Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.
Sapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationalSapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of
Synonyms: R-THBPVorapaxar
go.drugbank.com/drugs/DB09030ApprovedVorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history … By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Synonyms: Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamateTolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. … It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Ferric oxide
go.drugbank.com/drugs/DB11576ApprovedInvestigationalIt is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite. … Iron(III) oxide or ferric oxide is the inorganic compound with the formula Fe2O3.
Mixtures: Cellzyme ON-TOX, Cellzyme ON-TOXCategories: Compounds used in a research, industrial, or household settingProbucol
go.drugbank.com/drugs/DB01599ApprovedInvestigationalWithdrawnA drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Categories: Compounds used in a research, industrial, or household settingFezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … effective treatments for VMS by relieving symptoms in as many as 95% of menopausal women.